Biotechnology company Engitix Ltd said on Monday that it plans to identify ECM-related drug targets in fibrostenotic inflammatory bowel disease (IBD) under a research collaboration with Morphic Therapeutic, a biopharmaceutical company.
Morphic will use Engitix's ECM platform to identify drug targets for potential future oral integrin drug candidates as treatments for fibrostenotic inflammatory bowel disease (IBD), an intestinal fibrosis complication that affects 30% of Crohn's Disease patients. IBD is characterised by chronic inflammation of the gastrointestinal (GI) tract, with two main types: ulcerative colitis and Crohn's Disease.
Using its proprietary MInT technology platform that leverages the unique understanding of integrin structure and biology, Morphic said it aims to advance treatments for patients suffering from autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer.
Pursuant to the collaboration, Engitix will apply its unique tissue-specific ECM platform to identify and characterise the expression of drug targets and cover integrin and non-integrin expression in fibrostenosis.
By incorporating human ECM, Engitix's in vitro models closely resemble the natural cell microenvironment and increase the probability that target identification can occur in a relevant and meaningful context.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients